imdelltra
Pharmaranks rates Imdelltra 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Imdelltra (Tarlatamab-Dlle) is a medication used to treat Lung Neoplasms.
Tarlatamab-Dlle · by Amgen Inc
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Tarlatamab-Dlle
- Form
- Kit
- Strength
- TARLATAMAB-DLLE 10MG · TARLATAMAB-DLLE 1MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- lung neoplasms
- Manufacturer
- Amgen Inc
- FDA application
- BLA761344
Storing Imdelltra, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “See Table 12 for maximum storage time of prepared IMDELLTRA infusion.”
- “Table 12 displays the maximum storage time for the prepared IMDELLTRA infusion bag.”
- “Maximum storage time includes total duration from the time of reconstitution of the vial of IMDELLTRA to the end of the infusion.”
- “°C to 8°C (36°F to 46°F) Prepared IMDELLTRA Infusion Bag 8 hours 7 days Discard the prepared IMDELLTRA infusion bag after maximum storage time (from time of reconstitution).”
May treat (source: NIH RxClass)
Dosage forms
Kit
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Imdelltra treat?
- Imdelltra (Tarlatamab-Dlle) may be used to treat lung neoplasms, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Imdelltra rated?
- pharmaranks gives Imdelltra a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Imdelltra?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Imdelltra. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Imdelltra?
- Imdelltra is marketed by Amgen Inc. You can see Amgen Inc's full profile, rating, and other products on pharmaranks.
- Is Imdelltra a brand-name or generic drug?
- Imdelltra is a brand-name product with the active ingredient Tarlatamab-Dlle.
- Is Imdelltra available over the counter?
- No. Imdelltra is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Imdelltra come in?
- Imdelltra is currently marketed as kit, per the FDA's National Drug Code Directory.
- Is Imdelltra FDA-registered?
- Imdelltra is on record with the U.S. FDA under application number BLA761344. You can verify this on its official FDA label.
- Has Imdelltra been recalled by the FDA?
- Imdelltra has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Imdelltra safe?
- There's no single safe-or-not verdict. pharmaranks gives Imdelltra a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about TARLATAMAB-DLLE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 3 reports naming TARLATAMAB-DLLE — the active ingredient in Imdelltra, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- acute respiratory failure1 reports
- asthenia1 reports
- chills1 reports
- depressed mood1 reports
- dyspnoea1 reports
- fatigue1 reports
- haemoglobin decreased1 reports
- headache1 reports
Read these as a signal, not a rate. A report does not mean TARLATAMAB-DLLE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Imdelltra head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
imdelltra
72/100